Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Classification of hepatic encephalopathy (HE)
- Acute liver failure (ALF)
- Neuropathology of ALF (1)
- Neuropathology of ALF (2)
- Microglial activation and neuroinflammation in ALF
- BBB breakdown in ALF- if infection\sepsis present
- Pathogenesis of HE in ALF - key role of ammonia
- Ammonia produced in the gut, removed by the liver
- Arterial ammonia predicts brain herniation in ALF
- Arterial NH3: risk factor of intracranial hypertension
- NH3 removal by brain: a neuroglial responsibility
- Ammonia removal by brain
- Selective gene expression alterations in ALF
- Glial fibrillary acidic protein (GFAP)
- Loss of GFAP mRNA in brain in ALF
- GFAP levels & brain edema - negative correlation
- Glutamate transporter EAAT-2
- Glutamate transporters in forebrain
- Decreased EAAT-2 mRNA/protein in brain in ALF
- Consequence of loss of EAAT-2 expression
- Extracellular brain glutamate & neurological status
- Systemic inflammation in ALF
- Neuroinflammation in ALF
- Microglial activation and neuroinflammation in ALF
- Brain cytokines in ALF
- Brain cytokine gene expression in ALF: in rat
- Brain cytokine gene expression in ALF: in mouse
- Therapeutic implications
- Do treatments act on neuroglial mechanisms?
- Mild hypothermia limits microglial activation (ALF)
- Mild hypothermia reduces brain cytokines (ALF)
- Mild hypothermia reduces brain cytokine levels
- NAC prevents neuroinflammation in ALF
- Minocycline
- Brain edema in ALF (minocyclin-protective effect)
- Minocyclin and brain pro-inflammatory cytokines
- Minocyclin and brain cytokine gene expression
- Take home messages (1)
- Take home messages (2)
- Acknowledgements
Topics Covered
- Classification of hepatic encephalopathy
- Acute liver failure
- Neuropathology of Acute liver failure
- Pathogenesis of hepatic encephalopathy in Acute liver failure: key role of ammonia
- Arterial NH3: risk factor of intracranial hypertension
- Selective gene expression alterations in Acute liver failure
- Glial fibrillary acidic protein (GFAP)
- Glutamate transporter EAAT-2
- Extracellular brain glutamate and neurological status
- Systemic inflammation in Acute liver failure
- Brain cytokines in Acute liver failure
- Therapeutic implications
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Butterworth, R.F. (2013, November 28). Hepatic encephalopathy in acute liver failure: a primary neurogliopathy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/FJTR6685.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Roger F. Butterworth, Speaker’s Bureau: Merz Pharmaceuticals, Frankfurt, Germany.
Hepatic encephalopathy in acute liver failure: a primary neurogliopathy
Published on November 28, 2013
33 min
A selection of talks on Neuroscience
Hide